Although immature still.

AZD9291 shows median progression-free of charge survival in patients with EGFRm T790M+ advanced NSCLC IMPRESS Study Results also Presented at the ESMO 2014 Congress Provide Increased Knowledge of Treatment Options for Individuals with EGFR Mutation Positive Advanced Non-Small Cell Lung Cancer who have Developed Acquired Level of resistance to First Line IRESSA Updated data from the ongoing AURA research of AZD9291 displays encouraging, although immature still, median progression free of charge survival of 9 .six months in sufferers with epidermal growth factor receptor mutation positive T790M+ advanced non-small cell lung cancers who acquired disease progression following treatment with an EGFR tyrosine kinase inhibitor .

‘Innovative product development partnerships have significant potential for addressing neglected diseases,’ said Dr. John Leonard, senior vice president, Pharmaceuticals, Research and Development, Abbott. ‘By merging the initial scientific expertise and sources of DNDi and Abbott, we look forward to accelerating research to find practical new treatment plans for people suffering from these diseases.’ Related StoriesDNDi announces effective completion of SCYX-7158 Phase I study for treatment of sleeping sicknessDNDi unveils programs to better react to the needs of neglected patientsDeadly parasite that causes Chagas disease widespread in Texas bugs’Abbott offers demonstrated a great degree of dedication by partnering with DNDi to share not merely its compounds, but also its expertise and resources.